Clinical trials: Initial
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with…
- Trial name
- NCT06146257
- Testing
- GLB-001
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- GluBio Therapeutics Inc.
Chronic Migraine
First Evaluation of a Craniofacial Nerve Stimulation System in Chronic Migraine
The purpose of this study is to demonstrate the safe use of the PRIMUS system in subjects with chronic migraine. This is a single-center, open label, prospective, early feasibility study to collect initial clinical data on the…
- Trial name
- SalviaBio (NCT05858801)
- Testing
- PRIMUS
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Salvia BioElectronics
Advanced Pancreatic Cancer
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1)…
- Trial name
- NCT04239001
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Hallux Valgus Deformity
A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity
This is a single-center, randomized, double-blind, placebo-controlled, single ascending dose, sequential-group Phase 1 study. The study will be conducted utilizing a cohort design, with sequential groups of 8 subjects.
- Trial name
- NCT03307837
- Testing
- CA-008
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Concentric Analgesics
Breast Cancer (Triple Negative Breast Cancer (TNBC))
RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
The Mutanome Engineered RNA Immuno-Therapy (MERIT) study introduced a novel concept for Individualized Cancer Immunotherapy (IVAC®) to treat each patient with the relevant and immunogenic RNA vaccines for a given patient's tumor.
- Trial name
- TNBC-MERIT (NCT02316457)
- Testing
- IVAC_W_bre1_uID, IVAC_W_bre1_uID/IVAC_M_uID
- Where
- 4 sites in Germany, Sweden
- Volunteers
- 42 people
- Sponsor
- BioNTech SE
Head and Neck Neoplasms
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
This study will test an investigational study drug called patritumab. It is a 'randomized study' which means participants have an equal chance of being assigned to receive the experimental medication (patritumab) or a substance…
- Trial name
- NCT02633800
- Testing
- Patritumab, Cetuximab, Cisplatin
- Where
- 34 sites in Belgium, France and 5 more
- Volunteers
- 87 people
- Sponsor
- Daiichi Sankyo
Functional Mitral Regurgitation
Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR)
This is a prospective, multi-center, single-arm study to evaluate the VenTouch System for treatment of moderate to moderate-severe functional mitral valve regurgitation [FMR].
- Trial name
- NCT02671799
- Testing
- VenTouch System Implant
- Where
- 2 sites in Czechia, France
- Volunteers
- 15 people
- Sponsor
- Mardil Medical
Ovarian Cancer
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
This is a multicenter, open-label study of safety and efficacy of Quisinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced epithelial ovarian cancer, primarily…
- Trial name
- NCT02948075
- Testing
- Quisinostat, Paclitaxel, Carboplatin
- Where
- 6 sites in Russia
- Volunteers
- 31 people
- Sponsor
- NewVac LLC
Carcinoma, Non-Small-Cell Lung
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.
- Trial name
- NCT02668393
- Testing
- Docetaxel, Nintedanib
- Where
- 4 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer (SCLC)
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease…
- Trial name
- NCT01904253
- Testing
- TAS-102, Amrubicin (Japan), Topotecan (Japan/Europe)
- Where
- 23 sites in Germany, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Hepatocellular Carcinoma (HCC)
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the efficacy and safety of HLX10 + HLX04 vs Sorafenibas as the First-line Treatment in Patients with Locally Advanced or Metastatic HCC…
- Trial name
- NCT04465734
- Testing
- HLX10, HLX04, Sorafenib
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)
- Trial name
- RESTORE (NCT07732400)
- Testing
- VV-14303
- Where
- 3 sites in United States, New Zealand
- Volunteers
- 56 people
- Sponsor
- Kriya Therapeutics, Inc.
Solid Tumor
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
- Trial name
- NCT02216409
- Testing
- Hu5F9-G4
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Gilead Sciences
Critical Limb Ischemia (CLI)
Initial Feasibility Study of the STENTiT Resorbable Fibrillated Scaffold (RFS). The RFS is Intended to Restore Lumen Patency and Blood Flow to Infrapopliteal Arteries. The RFS is a Fully Electrospun Tubular Device With a Fibrillated Microarchitecture and Designed for Transcatheter Delivery
This is the First-In-Human feasibility study of the RFS for below the knee lesions in subjects who experience critical limb ischemia due to the peripheral artery disease.
- Trial name
- VITAL-IT 1 (NCT07006467)
- Testing
- Implantation of RFS
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Stentit
Healthy
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
A Phase 1, first in human, three-part, single centre study to assess the safety, tolerability, PK and PD of single ascending subcutaneous doses of HTL0030310 in healthy subjects
- Trial name
- NCT03847207
- Testing
- HTL0030310, Pasireotide
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Male Hypogonadism
Time to Eugonadal Range, Time to Steady State and Drying Time
This is a multicenter, open-label, single arm trial to evaluate the time to eugonadal testosterone range after initial testosterone gel 2% application, time to steady state after after initiation of testosterone gel 2%, and…
- Trial name
- NCT01228071
- Testing
- testosterone gel 2%
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Actinic Keratosis
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by reflectance confocal microscopy.
- Trial name
- NCT01449513
- Testing
- Ingenol mebutate
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Healthy Volunteers
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
Phase 1, randomized, double-blind, placebo-controlled first-in-human study to investigate the safety, tolerability, PK and PD properties of single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404 in healthy…
- Trial name
- NCT04497662
- Testing
- KPL-404
- Where
- 2 sites in United States, Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Safety, Tolerability
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.
- Conditions
- Safety, Tolerability, Pharmacokinetics, Healthy Participants
- Trial name
- NCT05143905
- Testing
- AZD7503
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in first-line therapy in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer.
- Trial name
- NCT01790217
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche